Physician profile
John May
NPI 1588674915
$3,699.87
in general payments reported to CMS, 2019-2025
16 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $131 · 2021: $210 · 2022: $183 · 2023: $421 · 2024: $1,122 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,875 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,874.52 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $735.64 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $719.19 | 2019-2025 | Cequa |
| Thea Pharma INC. | $399.50 | 2022-2025 | Iyuzeh |
| Abbvie INC. | $313.96 | 2023-2025 | |
| Alcon Vision LLC | $283.68 | 2025 | Tryptyr, Rocklatan, Hydrus Microstent |
| Allergan, INC. | $244.74 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $197.22 | 2019-2021 | |
| Dompe US, INC. | $188.33 | 2024-2025 | Oxervate |
| Nova Eye, INC. | $154.88 | 2025 | |
| Mallinckrodt Hospital Products INC. | $114.65 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $87.69 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $65.80 | 2022-2025 | Ryzumvi, Tyrvaya |
| Sight Sciences, INC. | $63.85 | 2020-2022 | |
| Astellas Pharma US INC | $53.71 | 2024-2025 | Izervay |
| Revance Therapeutics, INC. | $52.72 | 2025 | Daxxify |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $24.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.